Plain-English translation of NCT07704840 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called BMS-986368 to see if it can help reduce muscle stiffness (spasticity) that develops after a stroke. About 42 people will participate, and half will receive the medication while the other half receives a placebo (a pill with no active ingredient). Researchers want to know if this treatment can improve both the stiffness and how well your arm and hand work.
After a stroke, many people develop painful muscle stiffness that limits their ability to move and care for themselves. Current treatments don't work well for everyone and can have uncomfortable side effects, so doctors are looking for new options that could help more people recover better function.
You likely qualify if…
You likely don't qualify if…
The study lasts up to 24 weeks total. You'll start with a screening period of up to 4 weeks, then enter an 8-week treatment phase where you'll take a daily pill (either the new medication at increasing doses or placebo). After that, if you wish, you can continue for another 8 weeks where everyone receives the active treatment. Finally, there's a 4-week safety follow-up. You'll have regular visits to check how you're doing and monitor for any side effects.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States